| 1 |
Sodium-Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus Without Established Cardiovascular Disease: Do They Have a Role in Primary Prevention? |
|
|
| Dr Shailaja Kale,Dr Abd A Tahrani |
|
| Metabolism Open. 2021; : 100082 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 |
|
|
| Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra |
|
| International Journal of Diabetes in Developing Countries. 2020; 40(S1): 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study |
|
|
| Manash P Baruah,Sanjay Kalra |
|
| European Endocrinology. 2019; 15(2): 113 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis |
|
|
| Jennifer R Donnan,Catherine A Grandy,Eugene Chibrikov,Carlo A Marra,Kris Aubrey-Bassler,Karissa Johnston,Michelle Swab,Jenna Hache,Daniel Curnew,Hai Nguyen,John-Michael Gamble |
|
| BMJ Open. 2019; 9(1): e022577 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians |
|
|
| Awadhesh Kumar Singh,Ambika G. Unnikrishnan,Abdul H. Zargar,Ajay Kumar,Ashok K. Das,Banshi Saboo,Binayak Sinha,Kalyan Kumar Gangopadhyay,Pradeep G. Talwalkar,Samit Ghosal,Sanjay Kalra,Shashank Joshi,Surendra Kumar Sharma,Usha Sriram,Viswanathan Mohan |
|
| Diabetes Therapy. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis |
|
|
| Hongmei Wang,Jiadan Yang,Xi Chen,Feng Qiu,Juan Li |
|
| Clinical Therapeutics. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes |
|
|
| Habib Yaribeygi,Stephen L. Atkin,Amirhossein Sahebkar |
|
| Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(2): 1679 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
EFFICACY AND SAFETY OF ADDITION OF EMPAGLIFLOZIN IN DIABETIC PATIENTS UNCONTROLLED WITH GLIMEPIRIDE + METFORMIN + TENELIGLIPTIN |
|
|
| Pattanaik S.R |
|
| Journal of Evidence Based Medicine and Healthcare. 2018; 4(14): 1226 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
|
|
| Xia Dai,Zu-chun Luo,Lu Zhai,Wen-piao Zhao,Feng Huang |
|
| Diabetes Therapy. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
